| Literature DB >> 32612131 |
Carla Rognoni1, Diego Cuccurullo2, Ludovica Borsoi3, Luigi Bonavina4, Emanuele Asti4, Feliciano Crovella5, Uberto Andrea Bassi5, Gabriele Carbone5, Francesca Guerini6, Paolo De Paolis7, Silvia Pessione7, Vincenzo Maria Greco8, Elisabetta Baccarini8, Giorgio Soliani9, Carlo Sagnelli2, Clotilde Crovella2, Vincenzo Trapani10, Carlo De Nisco11, Emilio Eugeni12, Federico Zanzi13, Enrico De Nicola14, Antonio Marioni15, Alessandro Rosignoli16, Roberto Silvestro16, Rosanna Tarricone3,17, Micaela Piccoli10.
Abstract
With the development of newer meshes and approaches to hernia repair, it is currently difficult to evaluate their performances while considering the patients' perspective. The aim of the study was to assess the clinical outcomes and quality of life consequences of abdominal hernia repairs performed in Italy using Phasix and Phasix ST meshes through the analysis of real-world data to support the choice of new generation biosynthetic meshes. An observational, prospective, multicentre study was conducted in 10 Italian clinical centres from May 2015 to February 2018 and in 15 Italian clinical centres from March 2018 to May 2019. The evaluation focused on patients with VHWG grade II-III who underwent primary ventral hernia repair or incisional hernia intervention with a follow-up of at least 18 months. Primary endpoints included complications' rates, and secondary outcomes focused on patient quality of life as measured by the EuroQol questionnaire. Seventy-five patients were analysed. The main complications were: 1.3% infected mesh removal, 4.0% superficial infection requiring procedural intervention, 0% deep/organ infection, 8.0% recurrence, 5.3% reintervention, and 6.7% drained seroma. The mean quality of life utility values ranged from 0.768 (baseline) to 0.967 (36 months). To date, Phasix meshes have proven to be suitable prostheses in preventing recurrence, with promising outcomes in terms of early and late complications and in improving patient quality of life.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32612131 PMCID: PMC7329869 DOI: 10.1038/s41598-020-67821-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Summary of patient demographics and comorbid conditions.
| Age, years (range) | 59 (30–87) |
| Gender (male), n (%) | 35 (47%) |
| Body mass index, kg/m2 (range) | 30 (18–61) |
| Previous associated infections | 22 (29%) |
| Previous interventions | 53 (71%) |
| Obesity (BMI > 30) | 26 (35%) |
| Active smoking | 26 (35%) |
| Diabetes mellitus | 17 (23%) |
| Chronic obstructive pulmonary disease | 17 (23%) |
| Immunosuppression | 7 (9%) |
Operative characteristics: hernia defect and mesh dimensions, surgical approach, wound and hernia defect characteristics.
| VHWG grade II, n (%) | 40 (53%) |
| VHWG grade III, n (%) | 35 (47%) |
| Defect size, mean (range) | 431 cm2 (10–2,190) |
| Defect length, mean (range) | 21 cm (5–45) |
| Defect width, mean (range) | 20 cm (2–146) |
| Mesh dimension, mean (range) | 658 cm2 (70–3,020) |
| Surgical procedure time, mean (range) | 185 min (45–540) |
| Rives–Stoppa | 23 (30.7%) |
| Transversus abdominis release (TAR) | 25 (33.3%) |
| External oblique release | 9 (12.0%) |
| Open intraperitoneal onlay mesh (IPOM) | 13 (17.3%) |
| Endoscopic repair | 1 (1.3%) |
| Laparoscopic repair | 1 (1.3%) |
| Not reported | 3 (4.0%) |
| Intraperitoneal | 14 (19%) |
| Onlay | 3 (4%) |
| Retrorectus/preperitoneal | 55 (73%) |
| Not reported | 3 (4%) |
| Recurrent hernia repaired, n (%) | 32 (42.7%) |
| Incisional hernia | 53 (70.7%) |
| Incisional hernia with other concomitant procedures | 15 (20.0%) |
| Primary ventral hernia | 1 (1.3%) |
| Primary ventral hernia with other concomitant procedures | 1 (1.3%) |
| Parastomal hernia | 1 (1.3%) |
| Parastomal hernia with other concomitant procedures | 4 (5.3%) |
| Single location, n (%) | 55 (73%) |
| Midline hernias: | |
| Subxiphoidal | 7 (12.7%) |
| Epigastric | 13 (23.6%) |
| Umbilical | 17 (30.9%) |
| Infraumbilical | 6 (10.9%) |
| Suprapubic | 2 (3.6%) |
| Lateral hernias: | |
| Subcostal | 1 (1.8%) |
| Flank | 1 (1.8%) |
| Iliac | 8 (14.5%) |
| Lumbar | – |
| Multiple locations, n (%) | 20 (27%) |
| 20 (27%) | |
| Colostomy | 2 (10%) |
| Colostomy reversal | 1 (5%) |
| Bowel resection plus colostomy | 1 (5%) |
| Bowel resection | 10 (50%) |
| Rectal resection | 1 (5%) |
| Liver resection/segmentectomy | 2 (10%) |
| Spleno-pancreatic resection | 1 (5%) |
| Fistula removal | 1 (5%) |
| Uretero-enterostomy | 1 (5%) |
Figure 1Kaplan–Meier recurrence-free survival estimate.
Primary outcomes.
| Recurrence | 6 (8.0%) |
| Infected mesh removal | 1 (1.3%) |
| Superficial infection requiring procedural intervention | 3 (4.0%) |
| Deep/organ infection | – |
| Seroma requiring percutaneous drainage | 5 (6.7%) |
| Re-intervention | 4 (5.3%) |
Figure 2Change of EQ-5D-5L utility values over time (d days, m months).
Descriptive statistics of EQ-5D-5L utility values from Italian Hernia Club registry.
| Time | N | Mean | Std error | 95% CI | % floor | % ceiling | p* |
|---|---|---|---|---|---|---|---|
| Baseline | 56 | 0.768 | 0.026 | 0.716–0.820 | 0.0 | 19.6 | – |
| 8 days | 57 | 0.782 | 0.022 | 0.737–0.827 | 0.0 | 19.3 | 0.431 |
| 30 days | 59 | 0.878 | 0.016 | 0.845–0.911 | 0.0 | 32.2 | < 0.001 |
| 6 months | 60 | 0.945 | 0.011 | 0.923–0.966 | 0.0 | 56.7 | < 0.001 |
| 12 months | 60 | 0.960 | 0.010 | 0.940–0.980 | 0.0 | 66.7 | < 0.001 |
| 18 months | 63 | 0.971 | 0.008 | 0.954–0.987 | 0.0 | 76.2 | < 0.001 |
| 24 months | 52 | 0.974 | 0.009 | 0.955–0.993 | 0.0 | 78.8 | < 0.001 |
| 36 months | 20 | 0.967 | 0.019 | 0.928–1.000 | 0.0 | 80.0 | < 0.001 |
% floor refers to the percentage of patients reporting the lowest utility score (i.e. − 0.285). % ceiling refers to the percentage of patients reporting the highest utility score (i.e. 1);
*All p values refer to the change in mean utility with respect to baseline.
Mean change in EQ-5D-5L dimension scores from baseline (data from Italian Hernia Club registry).
| EQ-5D-5L dimensions | Baseline (mean) | Mean change from baseline | ||||||
|---|---|---|---|---|---|---|---|---|
| 8 days | 30 days | 6 months | 12 months | 18 months | 24 months | 36 months | ||
| Movement | 1.6 | 0.1 | − 0.3*** | − 0.6*** | − 0.5*** | − 0.5*** | − 0.6*** | − 0.6*** |
| Self-care | 1.5 | 0.2* | − 0.3*** | − 0.5*** | − 0.5*** | − 0.5*** | − 0.5*** | − 0.4*** |
| Usual activities | 1.9 | 0.0 | − 0.5*** | − 0.8*** | − 0.8*** | − 0.8*** | − 0.8*** | − 0.8*** |
| Pain/discomfort | 2.3 | − 0.3** | − 0.8*** | − 1.1*** | − 1.1*** | − 1.1*** | − 1.2*** | − 1.2*** |
| Anxiety/depression | 2.1 | − 0.2* | − 0.4*** | − 0.6*** | − 0.8*** | − 0.9*** | − 0.8*** | − 0.8*** |
The EQ-5D-5L dimensions can take on values from 1 (no problems) to 5 (extreme problems).
*p < 0.05, **p < 0.01, ***p < 0.001.